Xencor, Inc Shareholders' Equity
Xencor, Inc (XNCR) had Shareholders' Equity of $503.23 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $503.23M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $515.63M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $635.59M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $625.32M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $503.23M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $515.63M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $635.59M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $625.32M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $620.35M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $639.87M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $677.61M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $708.86M 10-Q/A · filed 2025-02-24 | $723.84M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $550.50M 10-Q/A · filed 2025-02-24 | $564.33M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $600.07M 10-Q/A · filed 2025-02-24 | $612.53M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $661.75M 10-K · filed 2025-02-27 | $668.80M 10-K · filed 2024-02-29 |
| 2023-09-30 | $669.01M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $678.88M 10-Q · filed 2023-11-08 | |
| 2023-03-31 | $683.58M 10-Q · filed 2023-11-08 | |
| 2022-12-31 | $727.50M 10-K/A · filed 2025-02-24 | |
| 2022-09-30 | $722.70M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $742.34M 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $763.02M 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $733.50M 10-Q · filed 2023-11-08 | |
| 2021-09-30 | $618.86M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $646.94M 10-Q · filed 2022-11-07 | |
| 2021-03-31 | $583.61M 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $572.44M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $568.48M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $570.64M 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $593.00M 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $593.20M 10-K · filed 2023-02-27 | |
| 2019-09-30 | $610.24M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $608.09M 10-Q · filed 2020-11-06 | |
| 2019-03-31 | $609.57M 10-Q · filed 2020-11-06 | |
| 2018-12-31 | $521.68M 10-K · filed 2022-02-24 | |
| 2018-09-30 | $532.27M 10-Q · filed 2019-11-05 | $532.27M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $519.18M 10-Q · filed 2019-11-05 | $519.18M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $537.66M 10-Q · filed 2019-11-05 | |
| 2017-12-31 | $316.46M 10-K · filed 2021-02-24 | $282.05M 10-K · filed 2018-02-28 |
| 2017-09-30 | $290.54M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $301.37M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $303.75M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $337.93M 10-K · filed 2020-02-25 | $313.95M 10-K · filed 2017-03-01 |
| 2016-09-30 | $202.42M 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $208.60M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $158.81M 10-Q · filed 2016-05-02 | |
| 2015-12-31 | $162.43M 10-K · filed 2018-02-28 | |
| 2015-09-30 | $153.31M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $162.07M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $169.30M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $59.29M 10-K · filed 2018-02-28 | |
| 2014-09-30 | $59.71M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $65.52M 10-Q · filed 2014-08-01 | |
| 2014-03-31 | $70.06M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $73.53M 10-K · filed 2017-03-01 | |
| 2012-12-31 | -$166.27M 10-K · filed 2016-03-08 | |
| 2011-12-31 | -$157.70M 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |